{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:08:45Z","timestamp":1787580525352,"version":"build-2736575974"},"reference-count":103,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T00:00:00Z","timestamp":1495238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Newcastle disease (ND) is one of the most important diseases of poultry worldwide. In the last decades, molecular research has gained a lot of new information about its causative agent, newcastle disease virus (NDV). In poultry industry, certain strains of NDV have been used for preventive vaccination for more than 60 years. NDV has also been applied to cancer patients with beneficial effects for about 50 years, but this is less well known. The molecular basis for these differential effects of NDV in birds and man have been elucidated in the last decades and are explained in this review. The anti-neoplastic and immune-stimulatory properties in non-permissive hosts such as mouse and man have to do with the strong type I interferon responses induced in these foreign species. Additionally, NDV has the potential to break various types of tumor resistances and also to affect liver fibrosis. A main section is devoted to the benefits of clinical application of NDV and NDV-based vaccines to cancer patients. Reverse genetics technology allowed developing NDV into a vector suitable for gene therapy. Examples will be provided in which genetically engineered NDV is being used successfully as vector against new emerging viruses.<\/jats:p>","DOI":"10.3390\/ijms18051103","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T01:47:33Z","timestamp":1495504053000},"page":"1103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1253-9145","authenticated-orcid":false,"given":"Volker","family":"Schirrmacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/nbt1369","article-title":"RNA interference against viruses: Strike and counterstrike","volume":"25","author":"Haasnoot","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/nyas.12668","article-title":"The reverse transcriptase-RNase H: From viruses to antiviral defense","volume":"1341","author":"Moelling","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00705-013-1679-6","article-title":"What contemporary viruses tell us about evolution: A personal view","volume":"158","author":"Moelling","year":"2013","journal-title":"Arch. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2016). Fifty years of clinical application of Newcastle Disease Virus: Time to celebrate!. Biomedicines, 4.","DOI":"10.3390\/biomedicines4030016"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5\u2032-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"ref_6","first-page":"287","article-title":"Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus","volume":"40","author":"Fournier","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ingle, H., Kumar, S., Raut, A.A., Mishra, A., Kulkarni, D.D., Kameyama, T., Takaoka, A., Akira, S., and Kumar, H. (2017). The microRNA miR-458 targets host and influenza virus transcripts to regulate antiviral immunity and restrict viral replication. Sci. Signal., 8.","DOI":"10.1126\/scisignal.aab3183"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.1253451","article-title":"Whole-genome analyses resolve early branches in the tree of life of modern birds","volume":"346","author":"Jarvis","year":"2014","journal-title":"Science"},{"key":"ref_9","unstructured":"Swayne, D.E., Glisson, J.R., McDougald, L.R., Nolan, L.K., Suarez, D.L., and Nair, V.L. (2013). Newcastle disease. Diseases of Poultry, Wiley-Blackwell. [13th ed.]."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.meegid.2016.01.008","article-title":"Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus)","volume":"39","author":"Dimitrov","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dimitrov, K.M., Afonso, C.L., Yu, Q., and Miller, P.J. (2016). Newcastle disease vaccines\u2014A solved problem or a continuous challenge?. Vet. Microbiol.","DOI":"10.1016\/j.vetmic.2016.12.019"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/science.122.3160.156.b","article-title":"Identification of vaccine strains of Newcastle disease virus","volume":"122","author":"Hanson","year":"1955","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/03079457.2012.697991","article-title":"The long view: A selective review of 40 years of Newcastle disease research","volume":"41","author":"Alexander","year":"2012","journal-title":"Avian Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1128\/JVI.80.6.2894-2903.2006","article-title":"Inhibition of receptor binding stabilizes Newcastle disease virus HN and F protein-containing complexes","volume":"80","author":"McGinness","year":"2006","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/biology2030936","article-title":"Oncolytic Newcastle disease virus as cutting edge between tumor and host","volume":"2","author":"Fournier","year":"2013","journal-title":"Biology"},{"key":"ref_16","unstructured":"Samal, S.K. (2011). Newcastle disease and related avian paramyxoviruses. The Biology of Paramyxoviruses, Caister Academic Press. [1st ed.]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00705-010-0632-1","article-title":"Development of an L gene real-time reverse-transcription PCR assay for the detection of an avian paramyxovirus type 1 RNA in clinical samples","volume":"155","author":"Fuller","year":"2010","journal-title":"Arch. Virol."},{"key":"ref_18","first-page":"5962","article-title":"Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication pattern","volume":"50","author":"Ahlert","year":"1990","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-61779-340-0_13","article-title":"Analysis of three properties of Newcastle disease virus for fighting cancer: Tumor-selective replication, antitumor cytotoxicity, and immunostimulation","volume":"797","author":"Fournier","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2009.05.033","article-title":"Evolutionary dynamics of Newcastle disease virus","volume":"391","author":"Miller","year":"2009","journal-title":"Virology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00705-016-2880-1","article-title":"Taxonomy of the order Mononegavirales: Update 2016","volume":"161","author":"Afonso","year":"2016","journal-title":"Arch. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virusres.2009.10.020","article-title":"The interferon antagonistic activities of the V protein from two strains of Newcastle disease virus correlate with their known virulence properties","volume":"147","author":"Alamares","year":"2010","journal-title":"Virus Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Molouki, A., and Peeters, B. (2017). Rescue of recombinant Newcastle disease virus: A short history of how it all started. Arch. Virol.","DOI":"10.1007\/s00705-017-3308-2"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00705-016-3065-7","article-title":"Rescue of recombinant Newcastle disease virus: Current cloning strategies and RNA polymerase provision systems","volume":"162","author":"Molouki","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.21821","article-title":"Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence","volume":"119","author":"Fiola","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_27","first-page":"971","article-title":"Expression of RIG-I, IRF3, IFN-\u03b2 and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus","volume":"34","author":"Wilden","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1128\/JVI.01553-09","article-title":"Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy","volume":"84","author":"Elankumaran","year":"2010","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectively for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/onc.2009.507","article-title":"Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus","volume":"29","author":"Puhlmann","year":"2010","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-1-59745-561-9_30","article-title":"Newcastle diasease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer","volume":"542","author":"Schirrmacher","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1743-422X-11-62","article-title":"Activation of the PKR\/eIF2a signaling cascade inhibits replication of Newcastle disease virus","volume":"11","author":"Zhang","year":"2014","journal-title":"Virol. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.gt.3300787","article-title":"Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus","volume":"6","author":"Schirrmacher","year":"1999","journal-title":"Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle disease virus selectively kills human tumor cells","volume":"52","author":"Reichard","year":"1992","journal-title":"J. Surg. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Ann. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_37","first-page":"85","article-title":"Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis","volume":"21","author":"Washburn","year":"2002","journal-title":"Int. J. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/cdd.2017.15","article-title":"Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing","volume":"24","author":"Garg","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4049\/jimmunol.176.1.401","article-title":"Defining the origins and evolution of the chemokine\/chemokine receptor system","volume":"176","author":"DeVries","year":"2006","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/viro.2002.1413","article-title":"Induction of interferon-\u03b1 and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemaggluzinin-neuraminidase but not F protein of Newcastle disease virus","volume":"297","author":"Zeng","year":"2002","journal-title":"Virology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/JVI.00211-09","article-title":"Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase","volume":"83","author":"Jarahian","year":"2009","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ijc.29202","article-title":"Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in ortheotopic glioma through the induction of immunogenic cell death","volume":"136","author":"Koks","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4049\/jimmunol.170.4.1814","article-title":"TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus","volume":"170","author":"Washburn","year":"2003","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/intimm\/8.4.491","article-title":"Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B","volume":"8","author":"Umansky","year":"1996","journal-title":"Int. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.4049\/jimmunol.0903453","article-title":"Antiviral response dictated by choreographed cascade of transcription factors","volume":"184","author":"Zaslavsky","year":"2010","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3892\/ijo.7.3.539","article-title":"Adhesive function of Newcastle disease virus hemagglutinin in tumor-host interaction","volume":"7","author":"Jurianz","year":"1995","journal-title":"Int. J. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.cgt.7700109","article-title":"Newcastle disease virus infection induces B7-1\/B7-2-independent T-cell costimulatory activity in human melanoma cells","volume":"7","author":"Termeer","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/eji.1830231032","article-title":"Viral hemagglutinin augments peptide-specific cytotoxic T cell responses","volume":"23","author":"Ertel","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_49","first-page":"840","article-title":"Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity","volume":"40","author":"Fournier","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2015.2213","article-title":"Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man vs. immune evasion by Ebola virus (Review)","volume":"36","author":"Schirrmacher","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0008-8749(90)90302-8","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-\u03b1\/\u03b2","volume":"126","author":"Zawatzky","year":"1990","journal-title":"Cell. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF00205796","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation","volume":"28","author":"Schild","year":"1989","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1111\/j.1432-1033.2004.04425.x","article-title":"Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein","volume":"271","author":"Horvarth","year":"2004","journal-title":"Eur. J. Biochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1128\/JVI.77.16.8676-8685.2003","article-title":"Newcastle disease virus V protein is associated with viral pathogenesis and functions as an \u03b1 interferon antagonist","volume":"77","author":"Huang","year":"2003","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host-range restriction","volume":"77","author":"Park","year":"2003","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nsmb.1765","article-title":"Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35","volume":"17","author":"Leung","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.chom.2014.07.008","article-title":"Ebola virus VP24 targets a unique NLS binding site on karyopherin \u03b1 5 to selectively compete with nuclear import of phosphorylated STAT1","volume":"16","author":"Xu","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.vaccine.2010.12.005","article-title":"Antitumor vaccination by Newcastle disease virus hemagglutinin-neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity","volume":"29","author":"Ni","year":"2011","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1586\/14760584.2014.854169","article-title":"Autologous tumor cell vaccines for post-operrative active-specific immunotherapy of colorectal carcinoma: Long-term patient survival and mechanism of function","volume":"13","author":"Schirrmacher","year":"2014","journal-title":"Exp. Rev. Vaccines"},{"key":"ref_60","first-page":"6017","article-title":"Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy","volume":"54","author":"Lorence","year":"1994","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1089\/hum.2011.207","article-title":"Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors","volume":"23","author":"Wie","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ijc.2910370416","article-title":"Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects","volume":"37","author":"Heicappell","year":"1986","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1517\/14712598.2015.1088000","article-title":"Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance","volume":"15","author":"Schirrmacher","year":"2015","journal-title":"Exp. Opin. Biol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/jir.2012.0095","article-title":"The oncolytic activity of Newcastle disease virus in clear cell carcinoma cells in normoxic and hypoxic conditions: The interplay between VHL and interferon-\u03b2 signaling","volume":"33","author":"Chng","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1478-3231.2009.01971.x","article-title":"Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice","volume":"29","author":"Li","year":"2009","journal-title":"Liver Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1637\/8407-071208-Reg.1","article-title":"Comparison of viral shedding following vaccination with inactivated and live Newcastle disease vaccines formulated with wild-type and recombinant viruses","volume":"53","author":"Miller","year":"2009","journal-title":"Avian Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2008.11.091","article-title":"A vaccine candidate of attenuated genotype VII Newcastle diasease virus generated by reverse genetics","volume":"27","author":"Hu","year":"2009","journal-title":"Vaccine"},{"key":"ref_70","first-page":"619","article-title":"Attenuated veterinary virus vaccine for the treatment of cancer","volume":"17","author":"Csatary","year":"1993","journal-title":"Cancer Detect. Prev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J. Neuro Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_73","first-page":"618","article-title":"Overview of phase I studies of intravenous administration of PV701, an oncolytic virus","volume":"5","author":"Lorence","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/jb.92.3.792-.1966","article-title":"Tumor immunity after viral oncolysis","volume":"92","author":"Cassel","year":"1966","journal-title":"J. Bacteriol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02987752","article-title":"A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate","volume":"9","author":"Cassel","year":"1992","journal-title":"Med. Oncol. Tumor Pharmacother."},{"key":"ref_77","first-page":"677","article-title":"Immunization with virus-modified tumor cells","volume":"25","author":"Schirrmacher","year":"1998","journal-title":"Semin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1200\/JCO.1997.15.7.2763","article-title":"Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast and ovarian cancer","volume":"15","author":"Ahlert","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_79","first-page":"21","article-title":"Newcastle disease virus-infected autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma","volume":"2","author":"Ockert","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_80","first-page":"947","article-title":"Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and sucutaneous R-IL-2 and IFN-\u03b1(2b)","volume":"6","author":"Pomer","year":"1995","journal-title":"Int. J. Oncol."},{"key":"ref_81","first-page":"21","article-title":"Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells","volume":"2","author":"Karcher","year":"2004","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1200\/JCO.2004.09.038","article-title":"Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit","volume":"22","author":"Steiner","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-008-0526-1","article-title":"Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial","volume":"58","author":"Schulze","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm914","article-title":"Bone marrow as a priming site for T-cell responses to blood-borne antigen","volume":"9","author":"Feuerer","year":"2003","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/86523","article-title":"Therapy of human tumors in NOD\/SCID mice with patient-derived reactivated memory T cells from bone marrow","volume":"7","author":"Feuerer","year":"2001","journal-title":"Nat. Med."},{"key":"ref_86","first-page":"1006","article-title":"A new strategy of cancer immunotherapy combining hyperthermia\/oncolytic virus pretreatment with specific autologous anti-tumor vaccination\u2014A review","volume":"2","author":"Schirrmacher","year":"2017","journal-title":"Austin Oncol. Case Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ijo.2014.2692","article-title":"Strong T-cell costimulation can reactivate tumor antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: Results from a phase I clinical study","volume":"46","author":"Schirrmacher","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4067\/S0716-97602012000100005","article-title":"Human dendritic cells sequentially matured with CD4+ T cells as a secondary signal favor CTL and long-term T memory cell responses","volume":"45","author":"Simon","year":"2012","journal-title":"Biol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3892\/ol.2014.2588","article-title":"Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report","volume":"8","author":"Schirrmacher","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2217\/imt.15.48","article-title":"Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: A case report","volume":"7","author":"Schirrmacher","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fonc.2014.00337","article-title":"Harnessing oncolytic virus-mediated anti-tumor immunity","volume":"4","author":"Schirrmacher","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_93","first-page":"74","article-title":"Armed therapeutic viruses\u2014A disruptive therapy on the horizon of cancer immunotherapy","volume":"5","author":"Bauzon","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fonc.2014.00224","article-title":"Multimodal cancer therapy involving oncolytic Newcastle Disease Virus, autologous immune cells and bispecific antibodies","volume":"4","author":"Schirrmacher","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fonc.2014.00191","article-title":"Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses","volume":"4","author":"Forbes","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fonc.2014.00145","article-title":"Chemotherapy and oncolytic virotherapy: Advanced tactics in the war against cancer","volume":"4","author":"Nguyen","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_97","first-page":"1359","article-title":"In vivo efficacy of systemic tumor targeting of a veral RNA vector with oncolytic properties using a bispecific adapter protein","volume":"29","author":"Bian","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.gt.3303095","article-title":"Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes","volume":"15","author":"Willuda","year":"2008","journal-title":"Gene Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JVI.01514-06","article-title":"Newcastle Disease Virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses","volume":"81","author":"Ge","year":"2007","journal-title":"J. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1073\/pnas.0703584104","article-title":"Newcastle Disease Virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens","volume":"104","author":"DiNapoli","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ayithan, N., Bradfute, S.B., Anthony, S.M., Stuthman, K.S., Bavar, S., Bray, M., and Ozako, K. (2015). Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118345"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2016.0097","article-title":"Mimiviruses and the human interferon system: Viral evasion of classical antiviral activities, but inhibition by a novel interferon-\u03b2 regulated immunomodulatory pathway","volume":"37","author":"Almeida","year":"2017","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1099\/0022-1317-82-7-1729","article-title":"High-level expression of a foreign gene from the most 3\u2032-proximal locus of a recombinant Newcastle disease virus","volume":"82 Pt 7","author":"Huang","year":"2001","journal-title":"J. Gen. Virol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/1103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:36:31Z","timestamp":1760207791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/1103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,20]]},"references-count":103,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["ijms18051103"],"URL":"https:\/\/doi.org\/10.3390\/ijms18051103","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,20]]}}}